Hubrecht Organoid Technology (HUB) was founded by the Hubrecht Institute, the University Medical Center Utrecht, and the Royal Netherlands Academy of Arts and Sciences (KNAW). HUB`s technology constitutes a paradigm-shifting platform for drug discovery and development, (pre)clinical patient stratification, predictive diagnostics, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics. HUB exploits the pioneering work of Prof. Dr. Hans Clevers, who discovered the HUB Organoid Technology to grow ‘mini-organs’ – organoids – from epithelial tissue-derived adult stem cells (ASCs).
3584 CM Utrecht
HUB Organoid Technology offers the most relevant in vitro preclinical models for screening the efficacy of drugs against various human diseases, such as cancer or cystic fibrosis. The unique capacity of HUB Organoids™ to recapitulate characteristics of the organ they originate from opens up new possibilities for research and drug development. Moreover, the long-term expansion of HUB Organoid cultures and access to a healthy counterpart provides a unique platform for drug discovery and development.
The living organoid biobank created by HUB and its partners consists of more than 1000 organoid cultures representing a variety of organs and disease models. For monogenetic diseases, the HUB living organoid biobank includes intestinal and lung organoids from Cystic Fibrosis patients and liver organoids from patients with metabolic diseases (e.g. alpha-1 antitrypsin, Crigler-Najjar, etc.). The HUB living organoid biobank also has an important representation of cancer models including breast, colorectal, head and neck, intestinal, liver, lung, ovarian, pancreatic tumour organoids. For some of these cancer models, organoids derived from normal (cancer-free) adjacent tissue are also available.
Using the living organoid biobank, HUB explores novel therapeutic strategies, including responsiveness to drug combinations to develop rules for patient stratification based on drug sensitivity in vitro. Connecting genomic heterogeneity and gene function to in vitro drug responsiveness will lead to the development of a road map for improved treatment strategies.
HUB exploits the pioneering work of Prof. Dr Hans Clevers, who discovered the HUB Organoid Technology to grow 'mini-organs' - organoids - from epithelial tissue-derived adult stem cells. The HUB Organoid model system is one of a kind as it was proven to be representative for individual human patients. This breakthrough invention allows us to establish a laboratory model of any epithelial disease, from any patient: a Patient in the Lab. The preclinical application of a model that represents the clinical patient response, will greatly impact the high attrition rate of drug development. Furthermore, it can fundamentally change clinical trials as well as a patient treatment since we have a method to predict each patient's response.
HUB is the global leader in the field of Organoid Technology with almost 150 patents and patent applications that provide broad coverage for its Organoid Technology across twenty different jurisdictions worldwide. HUB offers licenses to its proprietary diagnostics, and access to its 'living biobanks'.
Biotech and Pharma companies, CROs in different fields (pre-clinical/clinical).